Oncology · Breast CancerTrial Updateclinicalmid-term

Phase 3 Trial of SRG-514 in Triple Negative Breast Cancer Undergoing Surgery

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 6:01:44 AM

Assessment confidence: 80% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase 3 trial of SRG-514 could significantly influence treatment standards for triple negative breast cancer, a challenging oncology area. Its success may reshape surgical management practices and competitive dynamics in the oncology market. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 13 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential of SRG-514 to enhance surgical outcomes in TNBC and its implications for market positioning. The strongest clinical anchor is Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery (ClinicalTrials.gov), sub-indication match (breast cancer); entity match (surge therapeutics). In breast cancer, 0 regulatory and 4 competitive items passed relevance filtering for SURGE Therapeutics.

Competitive Pressure

The most relevant competitive pressure comes from BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer (Bristol Myers Squibb) — sub-indication match (breast cancer); sponsor/company relevance (bristol myers squibb). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer.

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes will be critical for potential regulatory approval, impacting the label and market entry strategy for SRG-514..

Key Risks

Elevated medium regulatory exposure for SURGE Therapeutics could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If SRG-514 proves effective, it could capture market share from existing therapies, enhancing SURGE Therapeutics' positioning in a competitive landscape.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for SURGE Therapeutics may improve if A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for SURGE Therapeutics may improve if The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety compared to standard-of-care.
Timeline shift beyond mid term would change urgency.
Outcome from BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Other | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer); Entity match (surge therapeutics)
FDA document
View source
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Merck)
FDA document
View source
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
ClinicalTrials.govmedium relevance
Sub-indication match (breast cancer)
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Sub-indication match (breast cancer)
FDA document
View source
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Bristol Myers Squibbhigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Roche)
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Sub-indication match (breast cancer)

Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Evaluating AI in postoperative rehabilitation of axillary web syndrome after breast cancer surgery: ChatGPT vs DeepSeek.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Repurposing nitazoxanide as a novel ferroptosis inducer for triple-negative breast cancer via dual disruption of iron homeostasis and the β-catenin/GPX4 axis.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

SURGE Therapeutics
SRG-514
triple negative breast cancer treatment protocols

Commercial impact

medium

If SRG-514 proves effective, it could capture market share from existing therapies, enhancing SURGE Therapeutics' positioning in a competitive landscape.

Regulatory impact

medium

The trial's outcomes will be critical for potential regulatory approval, impacting the label and market entry strategy for SRG-514.

What to watch

Monitor trial results and any announcements regarding efficacy and safety compared to standard-of-care.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.